Article Details
Retrieved on: 2021-05-11 09:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Patients in Scotland who are complement inhibitor treatment-naïve or have previously received Alexion's Soliris (eculizumab) for at least three months, ...
Article found on: www.pharmatimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here